CN114401720A - 多酪氨酸激酶抑制剂的晶型、制备方法及其用途 - Google Patents

多酪氨酸激酶抑制剂的晶型、制备方法及其用途 Download PDF

Info

Publication number
CN114401720A
CN114401720A CN202080063504.1A CN202080063504A CN114401720A CN 114401720 A CN114401720 A CN 114401720A CN 202080063504 A CN202080063504 A CN 202080063504A CN 114401720 A CN114401720 A CN 114401720A
Authority
CN
China
Prior art keywords
crystalline form
pyridin
cancer
compound
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080063504.1A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·雷佩尔
斯蒂芬·L·雷佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of CN114401720A publication Critical patent/CN114401720A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080063504.1A 2019-09-10 2020-09-09 多酪氨酸激酶抑制剂的晶型、制备方法及其用途 Pending CN114401720A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898469P 2019-09-10 2019-09-10
US62/898,469 2019-09-10
PCT/US2020/049986 WO2021050580A1 (en) 2019-09-10 2020-09-09 Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof

Publications (1)

Publication Number Publication Date
CN114401720A true CN114401720A (zh) 2022-04-26

Family

ID=74866002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080063504.1A Pending CN114401720A (zh) 2019-09-10 2020-09-09 多酪氨酸激酶抑制剂的晶型、制备方法及其用途

Country Status (6)

Country Link
US (1) US12466838B2 (enExample)
EP (1) EP4027999A4 (enExample)
JP (2) JP2022546861A (enExample)
CN (1) CN114401720A (enExample)
CA (1) CA3150267A1 (enExample)
WO (1) WO2021050580A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116963734A (zh) * 2021-03-10 2023-10-27 米拉蒂治疗股份有限公司 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240802A1 (en) 2021-05-10 2022-11-17 Teva Pharmaceuticals International Gmbh Solid state forms of sitravatinib salts and processes for preparation thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
WO2017029362A1 (en) * 2015-08-19 2017-02-23 Sandoz Ag Asymmetric bisamidation of malonic ester derivatives
CN109384799A (zh) * 2018-11-12 2019-02-26 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物
CN111971286A (zh) * 2018-01-18 2020-11-20 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2091910T3 (pl) * 2006-12-06 2015-02-27 Conatus Pharmaceuticals Inc Postacie krystaliczne kwasu (3S)-3-[N-(N’-(2-tert-butylofenylo)oksamylo)alaninylo]amino-5-(2’,3’,5’,6’-tetrafluorofenoksy)-4-oksopentanowego
US8907091B2 (en) * 2007-08-29 2014-12-09 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
WO2017029362A1 (en) * 2015-08-19 2017-02-23 Sandoz Ag Asymmetric bisamidation of malonic ester derivatives
CN111971286A (zh) * 2018-01-18 2020-11-20 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
CN109384799A (zh) * 2018-11-12 2019-02-26 深圳海王医药科技研究院有限公司 一种多靶点激酶抑制剂化合物的晶型a及制备方法和含有其的药物组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116963734A (zh) * 2021-03-10 2023-10-27 米拉蒂治疗股份有限公司 多重酪胺酸激酶抑制剂的结晶盐、其制备方法及用途

Also Published As

Publication number Publication date
WO2021050580A1 (en) 2021-03-18
EP4027999A4 (en) 2023-08-16
US20220402936A1 (en) 2022-12-22
JP2022546861A (ja) 2022-11-09
CA3150267A1 (en) 2021-03-18
US12466838B2 (en) 2025-11-11
EP4027999A1 (en) 2022-07-20
JP2025102940A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
KR102519922B1 (ko) 트리아졸로피리미딘 화합물의 결정질 형태
TWI743631B (zh) TGFβ抑制劑之新穎多晶型
US8329912B2 (en) Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
KR20140075703A (ko) 프리도피딘 하이드로클로라이드의 다형 형태
WO2023116895A1 (zh) Kras抑制剂的多晶型物及其制备方法和用途
JP2025102940A (ja) マルチチロシンキナーゼ阻害剤の結晶形、調製方法およびその使用
KR20190133724A (ko) (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노)프로판아미드의 다형체 및 고체 형태, 및 이의 제조 방법
KR102142797B1 (ko) 피리디닐아미노피리미딘 유도체의 메실레이트 염의 결정질 형태, 그의 제조 방법, 및 그의 용도
US20240174669A1 (en) Crystalline forms of a parp1 inhibitor
UA124728C2 (uk) Кристалічна фумаратна сіль (s)-[3,4-дифтор-2-(2-фтор-4-йодфеніламіно)феніл][3-гідрокси-3-(піперидин-2-іл)азетидин-1-іл]метанону
CA3222612A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
EA025561B1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
JP6178799B2 (ja) アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶
KR20140040671A (ko) 아프레피탄트 l-프롤린 조성물 및 공결정
HK40064763A (en) Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
WO2024188999A1 (en) Crystalline form
CN114026088A (zh) Jak2抑制剂的结晶形式
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
KR20240054327A (ko) Bcl-2 저해제의 고체 형태, 제조 방법 및 이의 용도
US20240391902A1 (en) Crystalline Form of Compound
US9981988B2 (en) Polymorphic forms and co-crystals of a c-Met inhibitor
US20240182449A1 (en) Crystalline forms of an mk2 inhibitor
WO2024245364A1 (en) Solid forms of a macrocyclic farnesyltransferase inhibitor and formulations thereof, and methods of preparing and using the macrocyclic compound and its solid forms
WO2025137366A2 (en) Solid-state forms of stat3 inhibitors and methods of use thereof
AU2021231396A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064763

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination